Reports Q4 revenue $6.81M, consensus $6.83M. "2022 was a significant year of transition for AnaptysBio as we refocused the company on broadly advancing our portfolio of best-in-class immune cell modulators. We are excited by the near-term initiation of our two global Phase 2b trials across rosnilimab, our PD-1 agonist, in rheumatoid arthritis and ANB032, our BTLA agonist, in atopic dermatitis. We believe their mechanisms of action have the potential to meaningfully impact large and significantly underserved patient populations, to restore immune balance by acting directly on cell types mediating disease pathology," said Daniel Faga, interim president and chief executive officer of AnaptysBio. "As we continue to progress our strategic portfolio review, we are well capitalized to deliver on multiple Phase 2 readouts across our wholly owned checkpoint agonists, as well as to advance ANB033, our anti-CD122 antagonist, through clinical proof-of-concept."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ANAB:
- AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
- AnaptysBio Announces Stock Repurchase Plan
- AnaptysBio board authorizes $50M stock repurchase plan
- AnaptysBio downgraded to Market Perform from Outperform at Raymond James